Please login to the form below
kidney disease
This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.
J&J’s Invokana aces diabetic kidney disease trial, setting up filings
Johnson &Johnson’s SGLT2 inhibitor Invokana worked so well in a trial involving diabetics with chronic kidney disease that the study has been halted early – potentially opening up a lucrative new ... Nearly half of all people with type 2 diabetes
Latest news
-
Daily Brief: AstraZeneca's new San Fran hoKeytruda triumphs again, Novo branches out
growing. Today is has unveiled a new alliance with San Diego-based biotech Epigen Biosciences for a novel compound to treat diabetic and chronic kidney disease. ... EPGN696 has demonstrated efficacy and safety in rodent models of kidney disease by
-
Sanofi warns of difficult few months as diabetes sales slump
The loss of patent protection for kidney disease drug Renvela/Renagel (sevelamer) also took its toll, according to chief executive Olivier Brandicourt, the architect of the turnaround plan at Sanofi, who ... Revenues were however fairly flat if exchange
-
Otsuka finally gets FDA OK for kidney disease drug
Otsuka finally gets FDA OK for kidney disease drug. Approval at last for rare disease treatment. ... to progression of kidney disease (measured using creatinine levels) and symptoms such as kidney pain and hypertension.
-
AZ taps Ionis for another drug, this time in NASH
It’s the third time AZ has taken up an option on an Ionis drug under a 2015 alliance in the area of cardiovascular, metabolic and kidney disease, after earlier deals ... for cardiovascular drug AZD8233 and kidney disease candidate AZD2373.
-
AZ finally gets EU nod for Veltassa rival Lokelma
The risk of hyperkalaemia increases significantly for patients with chronic kidney disease (CKD) and for those who take certain heart failure (HF) medicines that increase potassium levels in the blood.
More from news
Approximately 20 fully matching, plus 130 partially matching documents found.
Latest Intelligence
-
The invisible army
Studies with COPD and chronic kidney disease patients indicate that carers can have a positive influence on patient adherence to medication and healthy behaviours, thus driving positive outcomes in the process.
-
Deal Watch December 2016
1, 000. Akebia (US). Otsuka (Japan). Licence (US). Vadadustat: oral hypoxia-inducible factor (HIF) stabiliser in phase III for anaemia of chronic kidney disease. ... inflammatory bowel disease and multiple sclerosis.
-
Business as usual
He also cautioned delegates over 'dual use', describing a situation where ferric citrate was promoted at a kidney disease symposium. ... It was described as being FDA-approved - which it is, but not for the treatment of kidney disease.
-
Deal Watch February 2016
The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in disease pathways in indications such as muscle, neurodegenerative and liver diseases. ... licence. 105. †† Genexine/ Shanghai Chemo
-
Deal Watch December 2015
Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease . ... 397. Akebia (US). Mitsubishi. Collaboration, licence. Vadadustat for treatment of anaemia in chronic kidney disease.
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Sanifit appoints Alexander Gold chief medical officer
Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.
-
Spectrum appoints chief medical officer
of iron deficiency anaemia in adult patients with chronic kidney disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Making good practice common practice in rare disease
However, fatigue scores can’ t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Business Unit Head, Medical Communications, London
-
Excellent package
Subscribe to our email news alerts
- Moving annual total (MAT)
- Brexit rebels win vote on European Medicines Agency alignment
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- MaxCyte gets green light for solid tumour cell therapy
- NHS England to Vertex: come clean on Orkambi offer
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
90TEN Healthcare
90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
